Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease (AKD). MZE829 is an oral, small molecule APOL1 inhibitor that Maze is advancing as a potential treatment for people living with AKD, a subset of chronic kidney disease estimated to affect over one million patients in the United States alone.

“We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold Bernstein, M.D., Ph.D., president, R&D, and chief medical officer of Maze. “We have designed HORIZON to include a broad spectrum of patients, reflecting the diverse characteristics of AKD, beyond the narrow criteria of existing studies. By evaluating MZE829 across a wider population and organized by cohorts, we aim to demonstrate proof of concept and refine patient selection for future pivotal trials. With its potential to be a truly disease-modifying therapy, MZE829 represents hope for the many patients living with AKD, addressing a critical unmet need in kidney disease treatment.”

The HORIZON Study is a Phase 2, open-label basket design trial that will enroll AKD patients carrying the two high-risk APOL1 alleles (G1, G2), stratified by clinical phenotype and level of proteinuria, as well as patients who have type 2 diabetes.

Click the button below to read the entire Press Release:

Continue Reading The Press Release